What they found: Oral AOD-9604 reduced body fat by 18 to 22 % vs placebo, comparable to injection administration No changes in total body weight (because lean mass rose slightly) Decrease in plasma triglycerides by 30 % Decrease in resting free fatty acids (paradoxically, mobilization of fat from depots into oxidation) No GI side effects Why it matters: It suggested that AOD-9604 could work orally , a rare property for a peptide
Choosing the right provider for vitamin therapy matters
The biomimetic peptides present in the product are specifically designed to help with eyelash hair growth
But for someone new to peptide injections , the smaller volume means smaller margin for error
Different patient populations, different trial designs, different enrollment criteria, and different measurement protocols all introduce noise that makes precise numerical comparisons between CagriSema and tirzepatide unreliable
Dose escalation over 16 weeks